OncoMatch/Clinical Trials/NCT05735145
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
Is NCT05735145 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies paclitaxel combined with platinum for uterine cervical neoplasms.
Treatment: paclitaxel combined with platinum — This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy. By comparing simultaneous intensity-modulated radiotherapy and chemotherapy combined with adjuvant chemotherapy and simultaneous intensity-modulated radiotherapy and chemotherapy alone, based on the 2018 FIGO staging The clinical efficacy of locally advanced cervical cancer further clarifies the role of adjuvant chemotherapy in locally advanced cervical cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIB, IIIA, IIIB, IVA (FIGO 2018)
FIGO stage IB3, IIA2, IIB-IVA patients in 2018
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment — after diagnosis
Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect reached CR after treatment
Cannot have received: neoadjuvant chemotherapy and surgery
Patients who have received neoadjuvant chemotherapy and surgery
Lab requirements
Blood counts
serum hemoglobin >=100*10^9/l, blood platelet >= 100000/μl, absolute count of neutrophils>=1500/μl
Kidney function
serum creatinine <=1.5 unl or creatinine clearance >= 60 ml/min
Liver function
serum bilirubin <=1.5 unl, ast (sgot) and alt (sgpt)<= 1.5 unl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05735145 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior neoadjuvant chemotherapy and surgery disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIB or IIIA or IIIB or IVA is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages